Follow the company. Check the evidence.
Public records connected to stocks traded by Congress. See what changed, when it became public, and the original source.
ABBV: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-09-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Leadership change
Filed 8-K for an event or period dated 2026-10-28. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Financial results
Filed 8-K for an event or period dated 2026-10-30. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Issues related to the treatment of vitiligo Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process
Public: Oct 20, 2026, 10:55 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Issues related to the 340B drug discount program. Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to FDA regulation of pharmaceuticals.
Public: Oct 20, 2026, 5:36 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. Issues related to China WRT the BINSA bill. 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical supply chain. Prescription drug advertising issues. Issues related to TrumpRX. Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation.
Public: Oct 20, 2026, 4:24 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
S.1040, Drug Competition Enhancement Act Patent litigation reform issues and issues related to post-grant proceedings at the USPTO Value of intellectual property S. 864, HELP Copays Act H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act S. 2903, Safe Step Act H.R. 5509, Safe Step Act H.R. 8630, The Protecting Equal Access to Thyroid Act of 2026 Drug cost and pricing policy issues Patient affordability issues Issues related to the 340B program Issues related to data privacy Issues related to FDA communications Public Law 117-169 (formerly known as H.R. 5376, Inflation Redu
Public: Oct 20, 2026, 3:35 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Education around data privacy. Education about the drug approval process at FDA.
Public: Oct 20, 2026, 3:29 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
federal budget issues drug pricing in federal programs, transparency, prescription drug pricing and access, beneficiary access, IRA Part B, Part D, drug pricing and access, negotiation,
Public: Oct 20, 2026, 12:04 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Issues related to reimbursement of medications under Medicare Part B, including H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Public: Oct 19, 2026, 11:13 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
A lobbying activity report was filed. Income and expenses are separate reporting measures and must not be added together.
Public: Oct 19, 2026, 1:58 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
Drug pricing policies, implementation of IRA drug pricing policies, access and coverage, most-favored nation drug pricing policies, ORPHAN Cures Act implementation. Monitoring 232 investigations, monitoring tariffs, most favored nation drug pricing policies, pharmaceutical IP issues. H.R.830/S. 864, HELP Copays Act of 2023; Pharmacy Benefit Manager transparency, including Lower Costs, More Transparency Act, monitoring efforts around direct-to-consumer policies. 340B Reform, FDA drug approvals, monitoring Food is Medicine initiatives, importation of biopharmaceutical products, pharmaceutical su
Public: Oct 19, 2026, 12:05 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Issues regarding life sciences related matters. Issues regarding life sciences related matters.
Public: Oct 18, 2026, 8:38 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Leadership change
Filed 8-K for an event or period dated 2026-10-14. Leadership change.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
International tax issues and pharmaceutical pricing and access issues, and patent issues. International tax issues and pharmaceutical pricing and access issues, and patent issues.
Public: Oct 15, 2026, 2:38 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: third_quarter 2026 lobbying report
Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act. Issues related to reimbursement of medications under Medicare Part B, including H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act.
Public: Oct 8, 2026, 4:15 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Financial results
Filed 8-K for an event or period dated 2026-10-05. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Company disclosure
Filed 8-K for an event or period dated 2026-09-03. Company disclosure.
1 congressional household disclosed purchases in the past 90 days. See the trades
Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that CARAFATE (sucralfate) oral suspension, 1 gram (g)/10 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
Public: Sep 2, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA, Agency, or we) has determined that NAMENDA (memantine hydrochloride) tablets, 5 milligrams (mg) and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to these drug products, and it will allow FDA to continue to approve ANDAs that refer to the products as long as the ANDAs meet relevant legal and regulatory requirements.
Public: Sep 1, 2026Original source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Other company developments
Filed 8-K for an event or period dated 2026-08-18. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Other company developments
Filed 8-K for an event or period dated 2026-08-04. Other company developments.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: 10-Q financial filing
Filed 10-Q for an event or period dated 2026-06-30. Read the company report for its disclosures.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: Financial results
Filed 8-K for an event or period dated 2026-07-31. Financial results.
1 congressional household disclosed purchases in the past 90 days. See the trades
ABBV: second_quarter 2026 lobbying report
Patient Access to drug treatment therapies; and drug cost and drug pricing reform. Oversight of the pharmaceutical industry and drug pricing. Policies as they relate to PBMs Issues related to the budget and appropriations process Issues related to the treatment of vitiligo Medicare Part D policies. Monitoring Policies related to the 340b program. Issues related to the implementation of the Inflation Reduction Act Issues related to the budget and appropriations process
Public: Jul 20, 2026, 10:25 PM EDTOriginal source ↗1 congressional household disclosed purchases in the past 90 days. See the trades
Connections describe public records, not evidence of wrongdoing or a prediction of returns. Event dates can precede publication by days or months. When a source has no public-release timestamp, we show when we first observed it.
Source coverage
Coverage is growing across companies already tracked here. A scan can return no matching records. This feed is not a complete record of every filing or agency action.
- SEC EDGAR
- Current across tracked companies505 of 505 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:26 PM EST
- USAspending
- Collection in progress72 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- SAM.gov
- Awaiting company connections
- Lobbying disclosures
- Not yet scanned0 of 548 companies scanned in the past 12 hours
- Congress.gov
- Current across tracked companies5 of 5 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- Federal Register
- Collection in progress296 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:27 PM EST
- Regulations.gov
- Partial coverage — some requests unavailable32 of 53 companies scanned in the past 12 hoursLatest successful company scan: Nov 12, 2026, 2:19 PM EST
- FEC campaign finance
- Stale — refresh overdue0 of 548 companies scanned in the past 12 hoursLatest successful company scan: Nov 11, 2026, 1:28 PM EST